BioCorRx Inc (BICX) reports earnings

The report was filed on March 31, 2025

We may earn a commission from links on this page.
In This Story

BioCorRx Inc (BICX0.00%). has submitted its Form 10-K filing for the fiscal year ended December 31, 2024.

The filing details the company's financial performance, highlighting a net loss of $5,106,124 for the year, compared to a net loss of $3,766,913 in the previous year.

Total revenues for the year decreased to $7,665 from $89,160 in 2023, primarily due to reduced sales and project support income.

Advertisement

Operating expenses increased to $5,130,170 from $3,876,956, driven by higher research and development costs and increased stock-based compensation.

Advertisement

BioCorRx Pharmaceuticals Inc., a majority-owned subsidiary, received a grant of $11,029,977 from the National Institutes of Health for the development of BICX104, a naltrexone implant for treating methamphetamine use disorder.

Advertisement

The company's cash position improved slightly, with cash on hand of $88,033 as of December 31, 2024, compared to $65,222 at the end of 2023.

BioCorRx continues to focus on developing addiction treatment solutions, including the BioCorRx Recovery Program and the UnCraveRx Weight Loss Management Program.

Advertisement

The company acknowledges the substantial doubt about its ability to continue as a going concern due to its historical net losses and the need for additional capital.

BioCorRx plans to address its financial challenges through additional equity or debt financing and by managing expenses.

Advertisement

The filing also highlights ongoing legal proceedings, including a judgment in favor of Pellecome, LLC, resulting in a liability of $332,503 for costs and attorneys' fees.

This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the BioCorRx Inc annual 10-K report dated March 31, 2025. To report an error, please email earnings@qz.com.